The drug consists of Nirmatrelvir tablets, which are packaged together and administered together with Ritonavir tablets.
Strides Pharma Science announced on Monday a sublicense agreement with the Medicines Patent Pool (MPP) to market a generic version of Pfizer’s Covid-19 oral treatment in 95 low- and middle-income markets. Pfizer’s oral Covid-19 treatment has received emergency use approval from the United States Food and Drug Administration (USFDA) for oral antiviral treatment for Covid-19.
Under the Kovidax brand name, the generic version of Pfizer’s oral drug will be launched on the market as part of Strides’ sublicense agreement with MPP. The product will be made at the company’s plant in Bengaluru. Strides said it had already secured its supplies of active pharmaceutical ingredients through a preferred partnership agreement.
The drug consists of Nirmatrelvir tablets, which are packaged together and administered together with Ritonavir tablets. The product is approved as an oral treatment for Covid-19 for emergency use in the US and many other countries, among high-risk adults and high-risk pediatric patients.
Pfizer’s oral Covid-19 treatment reduced the risk of hospitalization or death within three days of the onset of symptoms by 89% compared to a placebo.
It is given as a 300 mg dose of nirmatrelvir with 100 mg ritonavir tablet, given twice a day for five days.
This post Strides Pharma to manufacture Pfizer’s Covid-19 drug
was original published at “https://www.financialexpress.com/lifestyle/health/strides-pharma-to-manufacture-pfizers-covid-19-drug/2467291/”
